Lafyatis R - Search Results

1

Inhibition of β-Catenin Signaling in the Skin Rescues Cutaneous Adipogenesis in Systemic Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Trial of C-82.

Lafyatis R, Mantero JC, Gordon J, Kishore N, Carns M, Dittrich H, Spiera R, Simms RW, Varga J. Lafyatis R, et al. J Invest Dermatol. 2017 Dec;137(12):2473-2483. doi: 10.1016/j.jid.2017.06.032. Epub 2017 Aug 12. J Invest Dermatol. 2017. PMID: 28807667 Free PMC article. Clinical Trial.

2

Fibulin-2 and fibulin-5 alterations in tsk mice associated with disorganized hypodermal elastic fibers and skin tethering.

Lemaire R, Korn JH, Schiemann WP, Lafyatis R. Lemaire R, et al. Among authors: lafyatis r. J Invest Dermatol. 2004 Dec;123(6):1063-9. doi: 10.1111/j.0022-202X.2004.23471.x. J Invest Dermatol. 2004. PMID: 15610515 Free article.

3

Targeting fibrosis in systemic sclerosis.

Lafyatis R. Lafyatis R. Endocr Metab Immune Disord Drug Targets. 2006 Dec;6(4):395-400. doi: 10.2174/187153006779025766. Endocr Metab Immune Disord Drug Targets. 2006. PMID: 17214585 Review.

4

Increased expression of Wnt2 and SFRP4 in Tsk mouse skin: role of Wnt signaling in altered dermal fibrillin deposition and systemic sclerosis.

Bayle J, Fitch J, Jacobsen K, Kumar R, Lafyatis R, Lemaire R. Bayle J, et al. Among authors: lafyatis r. J Invest Dermatol. 2008 Apr;128(4):871-81. doi: 10.1038/sj.jid.5701101. Epub 2007 Oct 18. J Invest Dermatol. 2008. PMID: 17943183 Free article.

5

B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis.

Lafyatis R, Kissin E, York M, Farina G, Viger K, Fritzler MJ, Merkel PA, Simms RW. Lafyatis R, et al. Arthritis Rheum. 2009 Feb;60(2):578-83. doi: 10.1002/art.24249. Arthritis Rheum. 2009. PMID: 19180481 Free PMC article. Clinical Trial.

6

Increased frequency and compromised function of T regulatory cells in systemic sclerosis (SSc) is related to a diminished CD69 and TGFbeta expression.

Radstake TR, van Bon L, Broen J, Wenink M, Santegoets K, Deng Y, Hussaini A, Simms R, Cruikshank WW, Lafyatis R. Radstake TR, et al. Among authors: lafyatis r. PLoS One. 2009 Jun 22;4(6):e5981. doi: 10.1371/journal.pone.0005981. PLoS One. 2009. PMID: 19543397 Free PMC article.

7

Rituximab: a potential therapeutic advance in scleroderma: what is the evidence?

Simms RW, Lafyatis R. Simms RW, et al. Among authors: lafyatis r. Rheumatology (Oxford). 2010 Feb;49(2):201-2. doi: 10.1093/rheumatology/kep421. Epub 2009 Dec 23. Rheumatology (Oxford). 2010. PMID: 20032221 No abstract available.

8

Antagonistic effect of the matricellular signaling protein CCN3 on TGF-beta- and Wnt-mediated fibrillinogenesis in systemic sclerosis and Marfan syndrome.

Lemaire R, Farina G, Bayle J, Dimarzio M, Pendergrass SA, Milano A, Perbal B, Whitfield ML, Lafyatis R. Lemaire R, et al. Among authors: lafyatis r. J Invest Dermatol. 2010 Jun;130(6):1514-23. doi: 10.1038/jid.2010.15. Epub 2010 Feb 25. J Invest Dermatol. 2010. PMID: 20182440 Free PMC article.

9

Distinct evolution of TLR-mediated dendritic cell cytokine secretion in patients with limited and diffuse cutaneous systemic sclerosis.

van Bon L, Popa C, Huijbens R, Vonk M, York M, Simms R, Hesselstrand R, Wuttge DM, Lafyatis R, Radstake TR. van Bon L, et al. Among authors: lafyatis r. Ann Rheum Dis. 2010 Aug;69(8):1539-47. doi: 10.1136/ard.2009.128207. Epub 2010 May 24. Ann Rheum Dis. 2010. PMID: 20498209

10

Care of patients with scleroderma in the intensive care setting.

Farber HW, Simms RW, Lafyatis R. Farber HW, et al. Among authors: lafyatis r. J Intensive Care Med. 2010 Sep;25(5):247-58. doi: 10.1177/0885066610371181. Epub 2010 Jun 11. J Intensive Care Med. 2010. PMID: 20542965 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

251 results

Search Page